What is Cosentyx?
Cosentyx (secukinumab) is an injectable biologic drug that targets interleukin-17A (IL-17A), a protein involved in inflammation. Novartis manufactures it for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa in adults and children.[1]
How does Cosentyx work?
It binds to IL-17A, blocking its interaction with receptors on cells, which reduces inflammation in autoimmune conditions. Administered via subcutaneous injection, typically starting with a loading dose followed by weekly then monthly maintenance.[1]
What conditions does Cosentyx treat?
Approved for:
- Moderate-to-severe plaque psoriasis (ages 6+)
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Enthesitis-related arthritis (ages 4+)
- Hidradenitis suppurativa (adults)[1]
Common side effects and risks
Upper respiratory infections, diarrhea, and injection-site reactions occur frequently. Serious risks include infections (e.g., tuberculosis reactivation), inflammatory bowel disease flares, and hypersensitivity. Patients need screening for latent TB before starting.[1]
How much does Cosentyx cost?
List price is around $6,000-$7,000 per month in the US, varying by dose and insurance. Patient assistance programs from Novartis can lower costs for eligible users.[1]
Who makes Cosentyx and when do patents expire?
Novartis holds exclusive rights. Key US patents on the active ingredient expire in 2028-2031, with formulation and method patents extending to 2035-2036. Check DrugPatentWatch.com for latest expiration dates, litigation, and generic/biosimilar challenges: DrugPatentWatch - Cosentyx.[2]
How does Cosentyx compare to other biologics?
| Drug | Target | Key Conditions | Dosing Frequency |
|------|--------|----------------|------------------|
| Cosentyx (secukinumab) | IL-17A | Psoriasis, PsA, AS | Monthly after loading |
| Stelara (ustekinumab) | IL-12/23 | Psoriasis, PsA, Crohn's | Every 8-12 weeks |
| Tremfya (guselkumab) | IL-23 | Psoriasis, PsA | Every 8 weeks |
| Skyrizi (risankizumab) | IL-23 | Psoriasis, PsA, Crohn's | Every 12 weeks |
IL-17 inhibitors like Cosentyx may work faster for skin clearance in psoriasis than IL-23 drugs but have higher infection risks.[1]
Are biosimilars or generics available yet?
No approved biosimilars in the US as of 2024; first entry likely post-2028 pending patent challenges. Several companies (e.g., Alvotech, Samsung Bioepis) are developing candidates in Europe and elsewhere.[2]
[1] Cosentyx Prescribing Information, Novartis, 2024.
[2] DrugPatentWatch.com, Cosentyx Patent Details.